Claims for Patent: 7,897,588

Summary for Patent: 7,897,588

Title:	Agents and methods for enhancing bone formation
Abstract:	The present invention discloses agents and methods for inducing osteoblastic cellular differentiation, as well as the use of such agents and method to treat patients to maintain bone mass, enhance bone formation and/or bone repair. Exemplary agents include oxysterols, alone or in combination with particular oxysterols, or other agents known to assist in bone formation. The invention further includes medicaments including oxysterols for the treatment of bone disorders, local injections of oxysterols or cells (206) and implants (202) having agents or cells (203) to facilitate bone repair.
Inventor(s):	Parhami; Farhad (Los Angeles, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	10/524,945
Patent Claims:	1. A method of inducing osteoblastic differentiation and inhibiting adipocyte differentiation of mammalian mesenchymal stem cells (MSCs) comprising treating mammalian MSCs with at least one oxysterol, wherein the at least one oxysterol is selected from the group consisting of 20S-hydroxycholesterol, 22S-hydroxycholesterol, 22R-hydroxycholesterol and 25-hydroxycholesterol; and wherein the MSCs are treated with the at least one oxysterol under conditions that are effective to induce osteoblastic differentiation and to inhibit adipocyte differentiation of the MSC. 2. The method of claim 1, wherein the at least one oxysterol is a combination of oxysterols selected from the group consisting of 20S-hydroxycholesterol and 22R-hydroxycholesterol, and 20S-hydroxycholesterol and 22S-hydroxycholesterol. 3. The method of claim 1, further comprising treating the mammalian MSCs with at least one secondary agent selected from the group consisting of parathyroid hormone, sodium fluoride, insulin-like growth factor I, insulin-like growth factor II and transforming growth factor beta. 4. The method of claim 1, further comprising treating the mammalian MSCs with at least one secondary agent selected from the group consisting of cytochrome P450 inhibitors, phospholipase activators, arachadonic acid, COX enzyme activators, osteogenic prostanoids and ERK activators. 5. A method of stimulating mammalian cells to express a level of a biological marker of osteoblastic differentiation which is greater than the level of a biological marker in untreated cells, comprising exposing a mammalian cell to a selected dose of at least one oxysterol, wherein the at least one oxysterol is selected from the group consisting of 20S-hydroxycholesterol, 22S-hydroxycholesterol, 22R-hydroxycholesterol and 25-hydroxycholesterol, thereby resulting in a level of expression of a biological marker of osteoblastic differentiation which is greater than the level of a biological marker in untreated cells. 6. The method of claim 5, wherein the at least one oxysterol is a combination of oxysterols selected from the group consisting of 20S-hydroxycholesterol and 22R-hydroxycholesterol, and 20S-hydroxycholesterol and 22S-hydroxycholesterol. 7. The method of claim 5, further comprising treating the mammalian mesenchymal cells with at least one secondary agent selected from the group consisting of parathyroid hormone, sodium fluoride, insulin-like growth factor I, insulin-like growth factor II and transforming growth factor beta. 8. The method of claim 5, further comprising treating the mammalian mesenchymal cells with at least one secondary agent selected from the group consisting of cytochrome P450 inhibitors, phospholipase activators, arachadonic acid, COX enzyme activators, osteogenic prostanoids and ERK activators. 9. The method of claim 5 wherein the biological marker is an increase in at least one of alkaline phosphatase activity, calcium incorporation, mineralization or expression of osteocalcin mRNA. 10. The method of claim 5 wherein the mammalian cells are selected from the group consisting of MSCs, osteoprogenitor cells and calvarial organ cultures.

Details for Patent 7,897,588

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-03-29